{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T01:12:14Z","timestamp":1791594734129,"version":"4.3.4"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T00:00:00Z","timestamp":1730851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T00:00:00Z","timestamp":1730851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s10072-024-07819-8","type":"journal-article","created":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T07:06:11Z","timestamp":1730876771000},"page":"943-949","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Long-term efficacy and safety of tacrolimus in anti-MuSK antibody-positive myasthenia gravis: a retrospective single-center cohort study"],"prefix":"10.1007","volume":"46","author":[{"given":"Zhuajin","family":"Bi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengcui","family":"Gui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5369-7751","authenticated-orcid":false,"given":"Bitao","family":"Bu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,6]]},"reference":[{"key":"7819_CR1","doi-asserted-by":"publisher","first-page":"115872","DOI":"10.1016\/j.bcp.2023.115872","volume":"218","author":"X Chen","year":"2023","unstructured":"Chen X, Qiu J, Gao Z et al (2023) Myasthenia gravis: molecular mechanisms and promising therapeutic strategies. Biochem Pharmacol 218:115872. https:\/\/doi.org\/10.1016\/j.bcp.2023.115872","journal-title":"Biochem Pharmacol"},{"key":"7819_CR2","doi-asserted-by":"publisher","first-page":"1212757","DOI":"10.3389\/fimmu.2023.1212757","volume":"14","author":"AG Vakrakou","year":"2023","unstructured":"Vakrakou AG, Karachaliou E, Chroni E et al (2023) Immunotherapies in MuSK-positive Myasthenia Gravis; an IgG4 antibody-mediated disease. Front Immunol 14:1212757. https:\/\/doi.org\/10.3389\/fimmu.2023.1212757","journal-title":"Front Immunol"},{"key":"7819_CR3","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","volume":"87","author":"DB Sanders","year":"2016","unstructured":"Sanders DB, Wolfe GI, Benatar M et al (2016) International consensus guidance for management of myasthenia gravis: executive summary. Neurology 87:419\u2013425. https:\/\/doi.org\/10.1212\/WNL.0000000000002790","journal-title":"Neurology"},{"key":"7819_CR4","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1186\/s12883-021-02439-7","volume":"21","author":"S Zhao","year":"2021","unstructured":"Zhao S, Zhang K, Ren K et al (2021) Clinical features, treatment and prognosis of MuSK antibody-associated myasthenia gravis in Northwest China: a single-centre retrospective cohort study. BMC Neurol 21:428. https:\/\/doi.org\/10.1186\/s12883-021-02439-7","journal-title":"BMC Neurol"},{"key":"7819_CR5","doi-asserted-by":"publisher","first-page":"707","DOI":"10.3389\/fimmu.2020.00707","volume":"11","author":"LS Borges","year":"2020","unstructured":"Borges LS, Richman DP (2020) Muscle-specific kinase Myasthenia Gravis. Front Immunol 11:707. https:\/\/doi.org\/10.3389\/fimmu.2020.00707","journal-title":"Front Immunol"},{"key":"7819_CR6","doi-asserted-by":"publisher","first-page":"137561","DOI":"10.1016\/j.neulet.2023.137561","volume":"818","author":"X Yang","year":"2024","unstructured":"Yang X, Zhang W, Chang X et al (2024) Promising efficacy of low-dose rituximab in muscle specific kinase antibody positive Myasthenia Gravis. Neurosci Lett 818:137561. https:\/\/doi.org\/10.1016\/j.neulet.2023.137561","journal-title":"Neurosci Lett"},{"key":"7819_CR7","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1177\/1756285615571873","volume":"8","author":"JL Cruz","year":"2015","unstructured":"Cruz JL, Wolff ML, Vanderman AJ et al (2015) The emerging role of tacrolimus in myasthenia gravis. Ther Adv Neurol Disord 8:92\u2013103. https:\/\/doi.org\/10.1177\/1756285615571873","journal-title":"Ther Adv Neurol Disord"},{"key":"7819_CR8","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1111\/ene.13189","volume":"24","author":"T Kanai","year":"2017","unstructured":"Kanai T, Uzawa A, Kawaguchi N et al (2017) Adequate tacrolimus concentration for myasthenia gravis treatment. Eur J Neurol 24:270\u2013275. https:\/\/doi.org\/10.1111\/ene.13189","journal-title":"Eur J Neurol"},{"key":"7819_CR9","doi-asserted-by":"publisher","first-page":"204062232211225","DOI":"10.1177\/20406223221122538","volume":"13","author":"Z Bi","year":"2022","unstructured":"Bi Z, Cao Y, Liu C et al (2022) Remission and relapses of myasthenia gravis on long-term tacrolimus: a retrospective cross-sectional study of a Chinese cohort. Ther Adv Chronic Dis 13:20406223221122538. https:\/\/doi.org\/10.1177\/20406223221122538","journal-title":"Ther Adv Chronic Dis"},{"key":"7819_CR10","doi-asserted-by":"publisher","first-page":"516211","DOI":"10.3389\/fneur.2020.516211","volume":"11","author":"Z Zhang","year":"2020","unstructured":"Zhang Z, Guan Y, Han J et al (2020) Regional features of MuSK antibody-positive Myasthenia gravis in Northeast China. Front Neurol 11:516211. https:\/\/doi.org\/10.3389\/fneur.2020.516211","journal-title":"Front Neurol"},{"key":"7819_CR11","doi-asserted-by":"publisher","first-page":"1177249","DOI":"10.3389\/fimmu.2023.1177249","volume":"14","author":"Z Bi","year":"2023","unstructured":"Bi Z, Zhan J, Zhang Q et al (2023) Clinical and immune-related factors associated with exacerbation in adults with well-controlled generalized myasthenia gravis. Front Immunol 14:1177249. https:\/\/doi.org\/10.3389\/fimmu.2023.1177249","journal-title":"Front Immunol"},{"key":"7819_CR12","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1212\/wnl.55.1.16","volume":"55","author":"A Jaretzki 3rd","year":"2000","unstructured":"Jaretzki A 3rd, Barohn RJ, Ernstoff RM et al (2000) Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 55:16\u201323. https:\/\/doi.org\/10.1212\/wnl.55.1.16","journal-title":"Neurology"},{"key":"7819_CR13","first-page":"497","volume":"38","author":"KE Osserman","year":"1971","unstructured":"Osserman KE, Genkins G (1971) Studies in myasthenia gravis: review of a twenty-year experience in over 1200 patients. Mt Sinai J Med 38:497\u2013537","journal-title":"Mt Sinai J Med"},{"key":"7819_CR14","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1111\/j.1600-0404.2007.00877.x","volume":"116","author":"A Shibata-Hamaguchi","year":"2007","unstructured":"Shibata-Hamaguchi A, Samuraki M, Furui E et al (2007) Long-term effect of intravenous immunoglobulin on anti-MuSK antibody-positive myasthenia gravis. Acta Neurol Scand 116:406\u2013408. https:\/\/doi.org\/10.1111\/j.1600-0404.2007.00877.x","journal-title":"Acta Neurol Scand"},{"key":"7819_CR15","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1007\/s00415-017-8616-7","volume":"264","author":"L Wang","year":"2017","unstructured":"Wang L, Zhang S, Xi J et al (2017) Efficacy and safety of tacrolimus for myasthenia gravis: a systematic review and meta-analysis. J Neurol 264:2191\u20132200. https:\/\/doi.org\/10.1007\/s00415-017-8616-7","journal-title":"J Neurol"},{"key":"7819_CR16","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.intimp.2010.12.012","volume":"11","author":"CB Zhao","year":"2011","unstructured":"Zhao CB, Zhang X, Zhang H et al (2011) Clinical efficacy and immunological impact of tacrolimus in Chinese patients with generalized myasthenia gravis. Int Immunopharmacol 11:519\u2013524. https:\/\/doi.org\/10.1016\/j.intimp.2010.12.012","journal-title":"Int Immunopharmacol"},{"key":"7819_CR17","doi-asserted-by":"publisher","first-page":"633","DOI":"10.3349\/ymj.2019.60.7.633","volume":"60","author":"YH Kim","year":"2019","unstructured":"Kim YH, Shin HY, Kim SM (2019) Long-term safety and efficacy of Tacrolimus in Myasthenia Gravis. Yonsei Med J 60:633\u2013639. https:\/\/doi.org\/10.3349\/ymj.2019.60.7.633","journal-title":"Yonsei Med J"},{"key":"7819_CR18","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.pediatrneurol.2017.08.014","volume":"77","author":"C Liu","year":"2017","unstructured":"Liu C, Gui M, Cao Y et al (2017) Tacrolimus improves symptoms of children with Myasthenia Gravis Refractory to Prednisone. Pediatr Neurol 77:42\u201347. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2017.08.014","journal-title":"Pediatr Neurol"},{"key":"7819_CR19","doi-asserted-by":"publisher","first-page":"820205","DOI":"10.3389\/fneur.2022.820205","volume":"13","author":"Z Bi","year":"2022","unstructured":"Bi Z, Cao Y, Lin J et al (2022) Long-term improvement in a Chinese cohort of glucocorticoid-resistant childhood-onset Myasthenia Gravis patients treated with Tacrolimus. Front Neurol 13:820205. https:\/\/doi.org\/10.3389\/fneur.2022.820205","journal-title":"Front Neurol"},{"key":"7819_CR20","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jocn.2004.12.008","volume":"13","author":"Y Shimojima","year":"2006","unstructured":"Shimojima Y, Matsuda M, Gono T (2006) Tacrolimus in refractory patients with myasthenia gravis: coadministration and tapering of oral prednisolone. J Clin Neurosci 13:39\u201344. https:\/\/doi.org\/10.1016\/j.jocn.2004.12.008","journal-title":"J Clin Neurosci"},{"key":"7819_CR21","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1212\/01.wnl.0000228225.23349.5d","volume":"67","author":"E Bartoccioni","year":"2006","unstructured":"Bartoccioni E, Scuderi F, Minicuci GM et al (2006) Anti-MuSK antibodies: correlation with myasthenia gravis severity. Neurology 67:505\u2013507. https:\/\/doi.org\/10.1212\/01.wnl.0000228225.23349.5d","journal-title":"Neurology"},{"key":"7819_CR22","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1111\/ene.14039","volume":"27","author":"Y Nishida","year":"2020","unstructured":"Nishida Y, Takahashi YK, Kanai T et al (2020) Safety of tapering tacrolimus dose in patients with well-controlled anti-acetylcholine receptor antibody-positive myasthenia gravis. Eur J Neurol 27:100\u2013104. https:\/\/doi.org\/10.1111\/ene.14039","journal-title":"Eur J Neurol"},{"key":"7819_CR23","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1177\/1756285617721092","volume":"10","author":"L Zhou","year":"2017","unstructured":"Zhou L, Liu W, Li W et al (2017) Tacrolimus in the treatment of myasthenia gravis in patients with an inadequate response to glucocorticoid therapy: randomized, double-blind, placebo-controlled study conducted in China. Ther Adv Neurol Disord 10:315\u2013325. https:\/\/doi.org\/10.1177\/1756285617721092","journal-title":"Ther Adv Neurol Disord"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-024-07819-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-024-07819-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-024-07819-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T09:14:23Z","timestamp":1737969263000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-024-07819-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,6]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["7819"],"URL":"https:\/\/doi.org\/10.1007\/s10072-024-07819-8","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,6]]},"assertion":[{"value":"22 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors report no conflicts of interest in this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the Committee of Clinical Investigation at Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan China (NO. TJ-IRB20220748).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statement"}},{"value":"Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}